BRKR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

958.30M

-2.17%

0.649

-14.54%

803.82M

+0.3%

0.422

-10.23%

815.12M

+2.22%

0.411

+28.55%

Estimates Revision

The market is revising Downward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by -0.82% over the past three months. During the same period, the stock price has changed by 46.06%.

Revenue Estimates for FY2025

Revise Downward

-0.82%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.43%

In Past 3 Month

Stock Price

Go Up

+46.06%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 44.60 USD with a low forecast of 42.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

42.00

Averages

44.60

High

50.00

Current: 0.000

Low

42.00

Averages

44.60

High

50.00

TD Cowen

Hold

maintain

$42 -> $53

2026-01-07

New

Reason

TD Cowen

Price Target

$42 -> $53

2026-01-07

New

maintain

Hold

Reason

TD Cowen raised the firm's price target on Bruker to $53 from $42 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.

Guggenheim

Subbu Nambi

Buy

maintain

$45 -> $53

2026-01-05

New

Reason

Guggenheim

Subbu Nambi

Price Target

$45 -> $53

2026-01-05

New

maintain

Buy

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Bruker to $53 from $45 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

JPMorgan

NULL -> Overweight

maintain

$50 -> $55

2025-12-15

Reason

JPMorgan

Price Target

$50 -> $55

2025-12-15

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Bruker to $55 from $50 and keeps an Overweight rating on the shares. The firm updated models in the life science tools and diagnostics group.

BofA

Michael Ryskin

Buy

upgrade

$43 -> $60

2025-12-15

Reason

BofA

Michael Ryskin

Price Target

$43 -> $60

2025-12-15

upgrade

Buy

Reason

BofA analyst Michael Ryskin raised the firm's price target on Bruker to $60 from $43 and keeps a Buy rating on the shares. After having spent several days marketing with the company's CFO in Europe, the firm came away more encouraged by the anticipated 2026 recovery, both for the broader life science tools market and Bruker specifically, the analyst tells investors.

Barclays

NULL -> Overweight

maintain

$45 -> $55

2025-12-15

Reason

Barclays

Price Target

$45 -> $55

2025-12-15

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Bruker to $55 from $45 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Wells Fargo

Brandon Couillard

maintain

$48 -> $55

2025-12-15

Reason

Wells Fargo

Brandon Couillard

Price Target

$48 -> $55

2025-12-15

maintain

Reason

Wells Fargo analyst Brandon Couillard raised the firm's price target on Bruker to $55 from $48 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 24.05, compared to its 5-year average forward P/E of 26.60. For a more detailed relative valuation and DCF analysis to assess Bruker Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

26.60

Current PE

24.05

Overvalued PE

33.19

Undervalued PE

20.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

17.59

Current EV/EBITDA

14.96

Overvalued EV/EBITDA

20.95

Undervalued EV/EBITDA

14.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.29

Current PS

2.12

Overvalued PS

4.29

Undervalued PS

2.30

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 113.25% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 113.25% over the last month.

Sold

Bought

BRKR News & Events

Events Timeline

No data

News

7.5

12:42 PMNewsfilter

Bruker Corporation Secures $500 Million Superconductor Supply Agreements

6.5

2025-12-26Fool

Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Net Position Change of $29.54 Million

6.5

2025-12-26NASDAQ.COM

Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Valued at $29.54 Million

People Also Watch

Frequently Asked Questions

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 52.48 USD — it has decreased -1 % in the last trading day.

What is Bruker Corp (BRKR)'s business?

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.

What is the price predicton of BRKR Stock?

What is Bruker Corp (BRKR)'s revenue for the last quarter?

Bruker Corp revenue for the last quarter amounts to 860.50M USD, decreased -0.45 % YoY.

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

Bruker Corp. EPS for the last quarter amounts to -0.41 USD, decreased -251.85 % YoY.

What changes have occurred in the market's expectations for Bruker Corp (BRKR)'s fundamentals?

How many employees does Bruker Corp (BRKR). have?

Bruker Corp (BRKR) has 11396 emplpoyees as of January 09 2026.

What is Bruker Corp (BRKR) market cap?

Today BRKR has the market capitalization of 7.97B USD.